GLP-1 Drugs Show Promise Against Multiple Addictions Simultaneously
Finn's Take· TL;DR- GLP-1 drugs reduced substance use deaths by 50% and prevented new addictions across alcohol, opioids, and stimulants in large veteran study.
- Medications dampen dopamine in the brain's reward center, addressing the common neurobiological root of all addictions rather than targeting specific substances.
- Over a dozen clinical trials now testing GLP-1 drugs for addiction treatment, leveraging existing primary care networks to reach millions with substance use disorders.
Breakthrough Study Reveals Unprecedented Addiction Benefits
A groundbreaking study involving over 600,000 veterans has revealed that GLP-1 drugs may not just be promising treatments for alcohol use disorder, but also for other substance use disorders . This pattern — people losing cravings across a broad range of addictive substances from a single drug class — appears to be unprecedented in modern addiction medicine .
The research, published in BMJ, analyzed data from patients with Type 2 diabetes who were prescribed either GLP-1 medications like Ozempic and Wegovy or other diabetes drugs. The new results showed that among people with pre-existing substance use disorders, there were fewer emergency room visits, hospitalizations and deaths related to their substance use across the board .
In the group already struggling with addiction, there were 50% fewer deaths due to substance use among those taking GLP-1 drugs compared with those who were not. We also found 39% fewer overdoses, 26% fewer drug-related hospitalizations and 25% fewer suicide attempts .
Prevention Across All Major Substances
Perhaps even more remarkable, the drugs appeared to prevent addictions from developing in the first place. Among people with no prior substance use disorder, those taking GLP-1 drugs had an 18% lower risk of developing alcohol use disorder, a 25% lower risk of opioid use disorder and an approximately 20% lower risk of cocaine and nicotine dependence .
The fact that the results were consistent across substance types — alcohol, opioids, stimulants — "really elevates the notion that these medications are really acting on the root causes of all of these addictions," said Dr. Ziyad Al-Aly, who led the study at Washington University in St. Louis.
The protective effects weren't limited to specific demographics. In veterans with no history of a substance use disorder, GLP-1 drugs were associated with a 14 percent reduced risk across all substance use conditions, with the largest drop—25 percent—seen in opioid use disorders .
How the Drugs Work on Addiction
Researchers believe these medications work by targeting the brain's reward system. GLP-1 drugs seem to work by reducing the hormone dopamine in what's known as the brain's mesolimbic system. That is the center of the brain that is responsible for reward-signaling - motivation, stress - and that is a center that is co-opted or hijacked, if you will, by addiction .
Unlike traditional addiction medications that target specific substances, GLP-1 drugs bypass that logic entirely. They dampen dopamine signaling in the brain's reward center, the same circuitry that addiction hijacks regardless of the substance involved . This mechanism explains why the drugs appear effective across multiple addiction types simultaneously.
GLP-1 drugs reduced consumption of alcohol, cocaine, and nicotine in preclinical studies — and critically, they did so without causing nausea or other aversive side effects. This matters because it suggests the mechanism isn't simply making substances unpleasant. The drugs appear to be rewiring the reward calculation itself — making the craving quieter rather than the consequence louder .
Implications for Public Health
The implications could be transformative for the nearly 50 million Americans living with substance use disorders. These drugs are already embedded in the primary care ecosystem. They're prescribed by family doctors, endocrinologists, internists — physicians who already manage the comorbidities that travel alongside addiction .
This accessibility advantage is crucial because an estimated 3% of people with alcohol use disorder are ever prescribed effective medication. The biggest barrier isn't availability: it's stigma, shame, fear of judgment and discrimination .
Grigson is now leading a multisite clinical trial testing Ozempic as an opioid use disorder treatment. More than a dozen additional trials are already underway or actively enrolling, and several more are planned . These randomized controlled trials will be essential for confirming whether GLP-1 drugs genuinely cause these benefits and determining optimal dosing strategies for addiction treatment.